Hemostatic Effect of Intrauterine Instillation of Oxytocin in Hysteroscopic Myomectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-15

Study Completion Date

2022-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is no previous study on the hemostatic effect of intrauterine instillation of oxytocin in hysteroscopic myomectomy. All previous studies focused on intravenous administration of oxytocin.

This trial may modify the surgical environment in hysteroscopic myomectomy by decreasing intraoperative bleeding to a degree that the amount of distention medium required for uterine distention will be reduced with a better visibility and shorter operation time.

The standard treatment of symptomatic myomas is hysterectomy for women who have completed childbearing period, and myomectomy for women who wish to preserve fertility hysteroscopic myomectomy currently is the gold standard minimally invasive procedure for the management of symptomatic submucous fibroids. Success of hysteroscopic myomectomy depends on good visualization throughout the procedure, via the correct distending pressure, continuous irrigation and the use of electrosurgery to control bleeding. Prolonged procedures that need continuous irrigation under high pressure are associated with higher risk of excessive fluid absorption and intravasation syndrome due to opened blood vessels within the myometrial, moreover, the thermal damage of the healthy tissues is increased with the use of the coagulation current.

Oxytocin receptors exist in the non-pregnant uterus but the concentration of the receptors is much lower than in pregnancy. this is why the clinical use of oxytocin outside of pregnancy is limited Oxytocin acts on oxytocin receptors in the myometrium and fibroid tissue leading to uterine contraction and constriction of uterine vasculature due to uterine contraction and vaso-constrictive effect of oxytocin thus reducing uterine perfusion and results in reducing intraoperative bleeding.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Different Modalities for the Evaluation of Patients With Peri-menopausal Bleeding

NCT07309692

Perimenopausal Bleeding

RECRUITING NA

Effectiveness of Warm Saline Distension Media on Relieving Pain in Office Hysteroscopy

NCT03111563

Hysteroscopy

UNKNOWN NA

Saline Sonohystrography and Office Hysteroscopy in Evaluation of Cases of Abnormal Uterine Bleeding

NCT03135353

Gynecologic Disease

UNKNOWN NA

Hysteroscopic Findings in Ovarian Polycystic and Unexplained Infertile Women.

NCT05042895

Infertility

RECRUITING NA

Safety and Efficacy of Distending Media Infusion by Manual Syringe Method for Hysteroscopic Procedures

NCT02101827

Hysteroscopic Surgery

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be subjected to:

1. History taking: including personal history, menstrual and obstetric history, medical and surgical history, medications.
2. Clinical examination; General and local with special concern about:

1. Size and position of the uterus
2. Transvaginal ultrasound to determine the number, size, location of fibroids and evaluation of the myometrial free margin that is defined as the minimum thickness between the outer edge of the fibroid and the inner edge of uterine serosa.
3. Laboratory evaluation: All participants will have routine blood tests: Complete Blood Count (CBC), serum creatinine, viral markers, coagulation profile and liver function tests.

Surgical procedure:

1. Office hysteroscopy will be performed the day before the procedure with the use of a 2-9 mm telescope with continuous-flow sheath (Hopkins II telescope 30 degrees: Karl storz) to assess and confirm the fibroid location, its intracavitary portion and to exclude any associated uterine pathology).
2. Hysteroscopy will be performed in the early proliferative phase (postmenstrual) in dorsal lithotomy position under general anesthesia, cervical dilatation will be done with Hegar dilators then resection of the submucous fibroid using monopolar resectoscope using 1,5% glycine as a distension medium by single operator to avoid inter-observer variability.
3. The intervention group (oxytocin group) will receive 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine). While in the control group a sterile bacteriostatic water ampule in the same form will be added to every 1000 ml of the distending medium (1,5% Glycine).
4. After completing the procedure, the surgeon will complete a record scale to document estimated blood loss, rating the bleeding (0: no bleeding, I; mild bleeding, II: moderate bleeding, III: severe bleeding, IV: severe bleeding with clots). Also will document the clarity of visual field using 3 point likert scale as (poor, fair, good).
5. Post operative settings:

* the duration of surgery and the volume of injected media will be calculated and documented.
* all patients will be subjected to postoperative hemoglobin 24 hours after the procedure, any intraoperative or postoperative complications will be documented

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leiomyoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled double blinded clinical trial.

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

The allocation will be concealed in sealed, sequentially numbered, white envelopes which will be prepared by a statistician where the drug will be covered with adhesive tape and handed over to the data collector. each woman will collect the corresponding sealed envelope directly from the data collector and it will be opened just before application of the drug.

the surgeon, the assistant and the nurse performing the procedure and the patient will be blinded to the medication drug which will be used inside the distention medium.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A (Oxytocin group):

30 women will undergo a hysteroscopic myomectomy with the use of 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine ).

Group Type ACTIVE_COMPARATOR

Oxytocin

Intervention Type DRUG

intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy

Group B (Placebo group):

30 women will undergo hysteroscopic myomectomy with the use of a sterile bacteriostatic water ampule in the distending medium (1,5% glycine).

Group Type PLACEBO_COMPARATOR

sterile bacteriostatic water ampule

Intervention Type OTHER

a placebo drug similar in shape to oxytocin ampules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxytocin

intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy

Intervention Type DRUG

sterile bacteriostatic water ampule

a placebo drug similar in shape to oxytocin ampules

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

syntocinon

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Symptomatic patient (Menorrhagia, recurrent pregnancy loss or infertility).
2. 1 or 2 submucous uterine myoma diagnosed by ultrasound with a diameter less than 4 cm
3. Myoma with FIGO 0 or 1.
4. Body mass index less than 35.

Exclusion Criteria

1. Pregnancy
2. Active pelvic infection
3. history of bleeding disorder or patient on anti-coagulant.
4. hepatic and renal diseases.
5. history of ischemic heart disease.
6. Patients with uterine structural abnormality or uterine septum.
7. Present or history of cervical or uterine cancer.
8. Preoperative administration of gonadotropin-releasing hormone analogues or danazol.
9. Allergy to glycine.
10. Patients with hypercoagulopathy.

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes